Source:http://linkedlifedata.com/resource/pubmed/id/18600081
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2008-7-7
|
pubmed:abstractText |
Glycosaminoglycans in normal human plasma, mainly represented by chondroitin sulfates and heparan sulfates/heparin (HSGAGs), show a specific distribution in the Cohn-Oncley fractions of human plasma. In the present study we investigated their effects on coagulation. Plasma was fractionated following the procedure of Cohn-Oncley, and each fraction was treated for extraction of glycosaminoglycans after extensive proteolysis; the anticoagulant activity in the extracted samples was measured by activated partial thromboplastin time (APTT). The effects of the samples containing HSGAGs on factor II and factor X activities, before and after treatment with heparinase I, were also measured. The molecular weight of HSGAGs was determined by polyacrylamide gel-electrophoresis. Cryoprecipitate and fraction I, fraction II+III, and fraction IV-1 (the fractions containing HSGAGs) prolonged the APTT, whereas fractions IV-4 and V had no effect on the APTT. Fractions containing HSGAGs showed effects on factor II and factor X activities that were sensitive to heparinase I treatment. The molecular weight of HSGAGs recovered in cryoprecipitate and fraction I was 15-18 kDa; that of HSGAGs recovered in fraction IV-1 was 12.0 kDa. In conclusion, these results demonstrate that HSGAGs of different molecular weight, endowed with anticoagulant activity, circulate in normal human plasma in association with specific proteins involved in the regulation of hemostasis; and that endogenous HSGAGs play a role in maintaining the antithrombotic/hemostatic balance in normal human plasma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants,
http://linkedlifedata.com/resource/pubmed/chemical/Factor X,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin,
http://linkedlifedata.com/resource/pubmed/chemical/Heparitin Sulfate,
http://linkedlifedata.com/resource/pubmed/chemical/Prothrombin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0957-5235
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
349-54
|
pubmed:meshHeading |
pubmed-meshheading:18600081-Adult,
pubmed-meshheading:18600081-Anticoagulants,
pubmed-meshheading:18600081-Blood Donors,
pubmed-meshheading:18600081-Factor X,
pubmed-meshheading:18600081-Female,
pubmed-meshheading:18600081-Heparin,
pubmed-meshheading:18600081-Heparitin Sulfate,
pubmed-meshheading:18600081-Humans,
pubmed-meshheading:18600081-Male,
pubmed-meshheading:18600081-Partial Thromboplastin Time,
pubmed-meshheading:18600081-Plasma,
pubmed-meshheading:18600081-Prothrombin
|
pubmed:year |
2008
|
pubmed:articleTitle |
Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors: preliminary study on a small group of recruits.
|
pubmed:affiliation |
Department of Experimental Pathology and Oncology, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|